{"entity":{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","aka":[],"tldr":"Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed.","summary":"Jennifer Chan directs the neuroendocrine and carcinoid tumour programme at Dana-Farber Cancer Institute. She was the study chair and first author of the 2024 New England Journal of Medicine report of the Alliance CABINET trial, in which cabozantinib improved progression-free survival compared with placebo in previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumours, supporting its approval in both groups.","asOf":"2026-09-18","links":[],"tags":["neuroendocrine","targeted-therapy","trialist"],"related":[],"cancers":["pancreatic-net","small-intestinal-net","lung-net","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-cabinet-cabozantinib-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Neuroendocrine tumours","Targeted therapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan%5BAuthor%5D"}],"papers":[]},"route":"/people/jennifer-chan/","neighbours":{"cancer":[{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"paper":[{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/"}]}}